Teva Blends Branded And Generic Mindsets To Boost Biosimilars
US Generics COO Says Teva Is ‘Uniquely Qualified’ To Succeed In The Biosimilar Arena
Executive Summary
Teva is “uniquely qualified” to succeed with biosimilars thanks to the dual branded and generic mindsets that it can bring to the table, Christine Baeder, senior vice president and chief operating officer of Teva’s US generics division, tells Generics Bulletin in the second part of an exclusive interview.
You may also be interested in...
Teva’s Baeder: We Need To ‘Crack The Nut’ Of Complex Generics
Industry and regulators need to collaborate to provide complex generics with the opportunity to build even further on the significant contributions already made by off-patent medicines to savings and access, Christine Baeder, senior vice president and chief operating officer of Teva’s US generics division, tells Generics Bulletin in the first part of an exclusive interview.
Teva’s Baeder: We Need To ‘Crack The Nut’ Of Complex Generics
Industry and regulators need to collaborate to provide complex generics with the opportunity to build even further on the significant contributions already made by off-patent medicines to savings and access, Christine Baeder, senior vice president and chief operating officer of Teva’s US generics division, tells Generics Bulletin in the first part of an exclusive interview.
UK Pioneers Tailored Biosimilars Pathway With Fresh Guidance
Updated guidance on the UK’s new licensing pathway for biosimilars – which will typically not require comparative efficacy data – has been published by the MHRA after a stakeholder consultation, receiving a warm welcome from the off-patent industry both locally and internationally.